Featured News

New Phase 2 Clinical Trial: TEV-CeD2 Study

What if there was a way to help your immune system become more tolerant of gluten? That’s the potential of VTP-1000, an investigational immunotherapy being studied in the AVALON celiac disease clinical trial.

A new international study published in the journal Gastroenterology sheds light on the extensive economic burden of celiac disease. In addition to the cost of gluten-free  foods, the authors address…

A new study from researchers at Penn State College of Medicine reveals significant differences in micronutrient deficiencies and healthcare utilization among minority patients with celiac disease (CeD) compared to their…

The Celiac Disease Foundation has joined forces with the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) Foundation to introduce two groundbreaking awards specifically designed to advance celiac disease research. These initiatives aim to foster novel research endeavors, emphasizing the importance for medical professionals to delve into the complexities of this lifelong autoimmune condition. 

Dr. Esen Sefik, PhD, an immunologist and an Associate Research Scientist in the Flavell Lab at Yale School of Medicine, is the recipient of the Celiac Disease Foundation–Takeda Early Career Research Award, an award designed to support promising early-career researchers working toward independent and productive research careers in celiac disease.  

Did you know that there are gluten-free summer camps that offer fun and peace of mind for children and teens with celiac disease? Learn about a few of the options available this summer!

The Celiac Disease Foundation today announced its Board of Directors re-appointments for 2024. The Board represents a diverse mix of professionals, patients, and caregivers who are deeply committed to advancing the Foundation’s mission of accelerating diagnosis, treatments, and a cure for celiac disease.  

The Celiac Disease Foundation is expanding its operations with the appointment of three senior-level staff. These roles are aligned with the Foundation’s latest strategic plan and ongoing work to accelerate diagnosis, treatments, and a cure for celiac disease – one of the world’s most prevalent genetic autoimmune diseases.

The Celiac Disease Foundation, a global leader in celiac disease patient advocacy, today announces its new relationship with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to provide resources for celiac disease patients and all consumers concerned about potential gluten in the company’s medications.